Comparison between High-Dose Pitavastatin and Moderate-Dose Pitavastatin combined with Ezetimibe on LDL-C Levels in Type II Diabetics.

Abstract

Objective: To compare pitavastatin 4 mg (high dose) with pitavastatin 2 mg (moderate dose) and ezetimibe combination on LDL-C in type II diabetics. Study Design: Observational study. Setting: National Medical Center (NMC) and PNS Shifa Hospital. Period: January and June 2022. Material & Methods: Fifty diagnosed type II diabetics on metformin, 25 in the monotherapy group (group A) and 25 in the combination therapy group (group B). Glycosylated hemoglobin and lipid profile tests were conducted in labs pre therapy and 3 months post therapy. LDL-C levels were recorded and compared. Result: Average LDL-C level drop of 13.51% occurred in the monotherapy group and 17.48% in the combination therapy group. Chi square test showed that LDL-C target levels (< 130 mg/dl) were reached in 33% patients in the monotherapy group and in 64% patients in the combination group. Conclusion: Pitavastatin monotherapy and combination therapy both lowered LDL-C levels, however, combination therapy with ezetimibe lowered levels by a greater degree and in a larger number of people.